Anzeige
Mehr »
Login
Montag, 09.09.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Tenbagger-ALARM! Aktie mit MEGA-Potenzial startet durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
583 Leser
Artikel bewerten:
(2)

United-Guardian, Inc.: United-Guardian Reports First Quarter Financial Results

HAUPPAUGE, N.Y., May 11, 2023 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) today announced financial results for the first quarter of fiscal year 2023, which ended on March 31, 2023.

Net sales decreased 34% compared to the prior year's first quarter, decreasing from $3,892,358 to $2,570,324. Net income for the quarter decreased by 17% from $911,465 ($0.20 per share) in 2022 to $756,081 ($0.16 per share) this year.

Beatriz Blanco, President of United-Guardian, stated, "The first quarter results reflect the world's current stagnating and challenging economic environment. The sales decrease was primarily attributable to a decrease in sales of the Company's cosmetic ingredients and medical lubricants, which was partially offset by an increase in sales of the Company's pharmaceutical and industrial products. Our main distributor for the Lubrajel® line of cosmetic ingredients experienced decreased demand in China and in other Asian countries, resulting from COVID-19 policies that were in place for much of 2022, and from significant customer inventory destocking. We are hopeful that demand trends will stabilize throughout the year as China's re-opening progresses. With this stabilization in demand, we hope to see increases in sales for the remainder of 2023. We remain committed to our growth strategy, and our path of change, reshaping the way we operate to support choices that are sustainable, innovative and deliver business growth."

United-Guardian is a manufacturer of cosmetic ingredients, medical lubricants, pharmaceuticals, and specialty industrial products.

Contact:Beatriz Blanco
(631) 273-0900
bblanco@u-g.com

NOTE: This press release contains both historical and "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company's expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the "safe harbor" provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company's business please refer to the company's reports and filings with the Securities and Exchange Commission.

RESULTS FOR THE QUARTERS ENDED
MARCH 31, 2023 and MARCH 31, 2022*

STATEMENTS OF INCOME
(UNAUDITED)

THREE MONTHS ENDED MARCH 31,
2023 2022
Net sales $2,570,324 $3,892,358
Costs and expenses:
Cost of sales 1,093,595 1,710,117
Operating expenses 517,946 546,749
Research and development 126,959 131,666
Total costs and expenses 1,738,500 2,388,532
Income from operations 831,824 1,503,826
Other income (expense):
Investment income 47,632 40,550
Net gain (loss) on marketable securities 72,701 (393,660)
Total other income (expense) 120,333 (353,110)
Income before provision for income taxes 952,157 1,150,716
Provision for income taxes 196,076 239,251
Net income $756,081 $ 911,465
Earnings per common share (basic and diluted) $ 0.16 $ 0.20
Weighted average shares - basic and diluted 4,594,319 4,594,319

* Additional financial information can be found at the company's web site at www.u-g.com.


© 2023 GlobeNewswire (Europe)
Vorsicht Crash! So sichere ich mein Aktienportfolio aktiv ab

Der schwarze Montag Anfang August, in Folge der temporären Liquidierung des sogenannten „Yen Carry-Trades“, vernichtete Milliarden an Anlegergeldern. Sogenannte Black Swan Events, also Ereignisse, die nichts und niemand vorhersagen kann, traten zuletzt im März 2020 beim Ausbruch der Corona-Pandemie auf.

Doch wie können Sie sich bei einem derartigen Ausverkauf und Verfall Ihres Depots schützen? Im folgenden kostenlosen Spezialreport wird aufgezeigt, wie man sein Depot mit diversen Strategien und den richtigen Instrumenten versichern kann.

Erweitern Sie Ihr Wissen und handeln Sie zukünftig wie die Profis, um vor dem nächsten schwarzen Schwan ihr Kapital in Sicherheit zu bringen.

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.